Methylstenbolone
Methylstenbolone is a steroid and an anti-inflammatory agent. Methylstenbolone inhibits nitric oxide production in macrophages and exhibits cytotoxicity against breast cancer cells and normal fibroblasts. Methylstenbolone can be used for the research of inflammation and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 6176-38-1
- Formula: C21H32O2
- Molecular Weight:316.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Methylstenbolone (1-25 μg/mL) potently inhibits nitric oxide production in J774.2 mouse macrophage cells with an IC50 of 10.1 μg/mL[3].
Methylstenbolone (6.25-50 µM; 48 h) is cytotoxic to MCF-7 human breast cancer cells (IC50 = 12.26 μg/mL) and toxic to BJ human fibroblast normal cells (IC50 = 8.69 μg/mL), but shows no cytotoxicity in NCI-H460 human lung cancer cells or HeLa human cervical cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7, NCI-H460, HeLa, BJ human fibroblast normal cells
-
Concentration:6.25, 12.5, 25, 50 µM
-
Incubation Time:48 h
-
Result:Exhibited cytotoxicity against MCF-7 breast cancer cells with an IC50 of 12.26 μg/mL.
Showed toxicity toward non-cancerous BJ human fibroblast cells with an IC50 of 8.69 μg/mL.
Showed no cytotoxicity in NCI-H460 human lung cancer cells or HeLa human cervical cancer cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:uPA+/+-SCID chimeric mice transplanted with primary human hepatocytes[1]
-
Dosage:1 mg
-
Administration:i.g.; single dose
-
Result:Detected no parent methylstenbolone compound and metabolites U1-U10, U13 in chimeric mouse urine.
Detected two dihydroxylated metabolites (U11 and U12) in both chimeric and nonchimeric mouse urine.
Chemical Information
-
CAS No. 6176-38-1
-
Molecular Weight 316.48
-
Formula C21H32O2
-
SMILES
CC1=C[C@]2([C@H](CC1=O)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(O)C)C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Geldof L, et al. Metabolism of methylstenbolone studied with human liver microsomes and the uPA⁺/⁺-SCID chimeric mouse model. Biomed Chromatogr. 2014;28(7):974-985. [Content Brief]
[2]. Piper T, et al. Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. Drug Test Anal. 2019;11(11-12):1644-1655. [Content Brief]
[3]. Aamer M, et al. New anti-inflammatory and non-cytotoxic metabolites of methylstenbolone obtained by microbial transformation. Bioorg Chem. 2022;129:106187. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Methylstenbolone
- 6176-38-1
- Drug Derivative
- BJ human fibroblast normal cells
- normal fibroblasts
- macrophages
- MCF-7 human breast cancer cells
- J774.2 mouse macrophage cells
- breast cancer cells
- human liver microsomes
- chimeric mouse urine
- NCI-H460 human lung cancer cells
- HeLa human cervical cancer cells
- Inhibitor
- inhibitor
- inhibit